Anna Elizabeth Rutherford, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Failure, Acute | 5 | 2012 | 165 | 1.570 |
Why?
|
| Keratin-18 | 2 | 2012 | 39 | 0.870 |
Why?
|
| Peripartum Period | 1 | 2018 | 133 | 0.600 |
Why?
|
| Fanconi Syndrome | 1 | 2016 | 35 | 0.560 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2016 | 69 | 0.560 |
Why?
|
| Peptide Fragments | 2 | 2012 | 5097 | 0.360 |
Why?
|
| Liver | 3 | 2021 | 7474 | 0.350 |
Why?
|
| Abdominal Pain | 1 | 2016 | 1063 | 0.350 |
Why?
|
| Hepatitis B, Chronic | 3 | 2019 | 393 | 0.320 |
Why?
|
| Liver Transplantation | 4 | 2016 | 2119 | 0.320 |
Why?
|
| Liver Regeneration | 1 | 2008 | 210 | 0.280 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 15540 | 0.280 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 270 | 0.280 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 1863 | 0.270 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 100 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 3923 | 0.230 |
Why?
|
| Fontan Procedure | 2 | 2020 | 778 | 0.230 |
Why?
|
| End Stage Liver Disease | 2 | 2021 | 314 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2019 | 2026 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2018 | 4687 | 0.220 |
Why?
|
| Spleen | 2 | 2021 | 2362 | 0.210 |
Why?
|
| Liver Diseases | 1 | 2011 | 1253 | 0.210 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 1320 | 0.200 |
Why?
|
| Hepatocytes | 1 | 2008 | 1211 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2020 | 4420 | 0.190 |
Why?
|
| Ascites | 2 | 2020 | 344 | 0.180 |
Why?
|
| Physicians | 1 | 2018 | 4567 | 0.180 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 2838 | 0.160 |
Why?
|
| Dermatofibrosarcoma | 1 | 2018 | 63 | 0.160 |
Why?
|
| Paracentesis | 1 | 2018 | 95 | 0.160 |
Why?
|
| Biopsy | 2 | 2023 | 6756 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2007 | 3200 | 0.150 |
Why?
|
| Facial Transplantation | 1 | 2020 | 226 | 0.150 |
Why?
|
| Trientine | 1 | 2016 | 11 | 0.150 |
Why?
|
| Ceruloplasmin | 1 | 2016 | 56 | 0.140 |
Why?
|
| Transaminases | 1 | 2016 | 199 | 0.130 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3508 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2016 | 380 | 0.130 |
Why?
|
| Gallbladder | 1 | 2016 | 302 | 0.130 |
Why?
|
| Apoptosis | 2 | 2008 | 9727 | 0.120 |
Why?
|
| Ribavirin | 1 | 2016 | 395 | 0.120 |
Why?
|
| Peritonitis | 1 | 2016 | 365 | 0.120 |
Why?
|
| Copper | 1 | 2016 | 366 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2021 | 1654 | 0.110 |
Why?
|
| Methotrexate | 1 | 2020 | 1727 | 0.110 |
Why?
|
| Heart Defects, Congenital | 2 | 2020 | 4584 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2018 | 695 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 3022 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2014 | 236 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2019 | 1092 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 1031 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2016 | 692 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 2214 | 0.100 |
Why?
|
| Depression | 1 | 2011 | 7766 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 367 | 0.090 |
Why?
|
| Bilirubin | 1 | 2012 | 425 | 0.090 |
Why?
|
| Massachusetts | 3 | 2018 | 8663 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 1339 | 0.090 |
Why?
|
| Aftercare | 1 | 2016 | 866 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 804 | 0.090 |
Why?
|
| Postpartum Period | 1 | 2016 | 1086 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2006 | 12720 | 0.080 |
Why?
|
| Coma | 1 | 2012 | 475 | 0.080 |
Why?
|
| Female | 17 | 2021 | 380194 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2018 | 4199 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4253 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2018 | 3528 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 5751 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 216 | 0.080 |
Why?
|
| Celiac Disease | 1 | 2015 | 785 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2016 | 1401 | 0.070 |
Why?
|
| Pregnancy | 5 | 2019 | 29144 | 0.070 |
Why?
|
| Humans | 23 | 2023 | 744343 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 197 | 0.070 |
Why?
|
| Adult | 12 | 2021 | 214055 | 0.070 |
Why?
|
| Iron | 1 | 2015 | 1774 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1786 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2886 | 0.070 |
Why?
|
| Skin | 1 | 2020 | 4364 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2011 | 8324 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 595 | 0.070 |
Why?
|
| ROC Curve | 1 | 2012 | 3527 | 0.060 |
Why?
|
| Logistic Models | 3 | 2016 | 13408 | 0.060 |
Why?
|
| Obesity | 1 | 2006 | 12745 | 0.060 |
Why?
|
| Bile Acids and Salts | 1 | 2006 | 367 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2016 | 2987 | 0.060 |
Why?
|
| Necrosis | 1 | 2008 | 1643 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 8949 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39050 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2016 | 5985 | 0.060 |
Why?
|
| Pruritus | 1 | 2006 | 361 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 560 | 0.050 |
Why?
|
| Prognosis | 4 | 2021 | 29063 | 0.050 |
Why?
|
| Male | 12 | 2021 | 350118 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 2011 | 880 | 0.050 |
Why?
|
| Biological Transport | 1 | 2006 | 2118 | 0.050 |
Why?
|
| Middle Aged | 9 | 2021 | 213383 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 4251 | 0.050 |
Why?
|
| Graft Survival | 1 | 2011 | 3737 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3870 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 2170 | 0.050 |
Why?
|
| Young Adult | 3 | 2016 | 56430 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2012 | 9849 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2012 | 10252 | 0.040 |
Why?
|
| Retrospective Studies | 7 | 2021 | 77449 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5686 | 0.040 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2000 | 204 | 0.040 |
Why?
|
| Boston | 1 | 2011 | 9313 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2011 | 4397 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2011 | 3114 | 0.040 |
Why?
|
| X Chromosome | 1 | 2000 | 814 | 0.040 |
Why?
|
| Risk Factors | 4 | 2016 | 72290 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2000 | 646 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2006 | 1580 | 0.030 |
Why?
|
| Comorbidity | 1 | 2011 | 10388 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15076 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12354 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 11366 | 0.030 |
Why?
|
| Aged | 5 | 2021 | 163280 | 0.030 |
Why?
|
| Placebos | 1 | 2020 | 1676 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 305 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 57776 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 15165 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2020 | 899 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 35421 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 1574 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.030 |
Why?
|
| Desensitization, Immunologic | 1 | 2018 | 483 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 2000 | 980 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2019 | 7729 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 2861 | 0.030 |
Why?
|
| Adolescent | 2 | 2012 | 85781 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1855 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12245 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 18370 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 23338 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 40075 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 53288 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 63114 | 0.020 |
Why?
|
| Gastroenterology | 1 | 2014 | 536 | 0.020 |
Why?
|
| Incidence | 1 | 2006 | 20947 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4149 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6489 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12026 | 0.020 |
Why?
|
| United States | 2 | 2019 | 69872 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23403 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2759 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2538 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15226 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10180 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 29786 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 13881 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 12804 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7279 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2014 | 4558 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 2000 | 318 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 21746 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 168757 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13695 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 3922 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 4894 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 40561 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6314 | 0.010 |
Why?
|
| Retina | 1 | 2000 | 2616 | 0.010 |
Why?
|
| Gene Expression | 1 | 2000 | 7799 | 0.000 |
Why?
|
| Gene Expression Profiling | 1 | 2000 | 9438 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 81183 | 0.000 |
Why?
|